Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly To Cease Development of Phase III Alzheimer's Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

The setback for semagacestat is yet another blow Lilly can ill afford as it aims to scale its patent cliff. It could also signal trouble for an entire class of related therapies.

You may also be interested in...



No Big Surprises From Lilly: Management Sticks To Its Guns On Strategy

With the loss of Zyprexa just months away, Eli Lilly management sought to reassure investors its strategy of focusing on its internal pipeline and core growth areas will pay off post-2014.

No Big Surprises From Lilly: Management Sticks To Its Guns On Strategy

With the loss of Zyprexa just months away, Eli Lilly management sought to reassure investors its strategy of focusing on its internal pipeline and core growth areas will pay off post-2014.

On Q3 Earnings Call, Lilly Vows To Stay Its Current Course Despite Late-Stage Pipeline Setbacks

As analysts call for transformative M&A, executives talked up Lilly's modest diversification efforts, including its animal health business, Elanco, and strong Japanese sales.

Related Content

Topics

UsernamePublicRestriction

Register

PS071046

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel